News

Anne Wojcicki regains control of 23andMe, the company she co-founded and led as CEO, through her nonprofit TTAM with a $305 million bid at a bankruptcy auction.
In a surprise twist, 23andMe founder and former CEO Anne Wojcicki is set to regain control of the DNA company's assets, according to a press release from 23andMe. In May, a company called ...
23andMe co-founder Anne Wojcicki is slated to regain control of her DNA-testing company after a nonprofit she controls outbid rivals in a bankruptcy auction. TTAM Research Institute, a nonprofit ...
Former 23andMe CEO Anne Wojcicki now runs TTAM Research Institute, which outbid Regeneron in an auction for the bankrupt ...
Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' offer for the DNA-testing company in a bankruptcy auction.
Former 23andMe CEO Anne Wojcicki is set to regain control of the genetic testing firm she led to bankruptcy after outbidding a pharmaceutical company at an auction. The sale came on Monday after a ...
A nonprofit run by Anne Wojcicki, the cofounder and former CEO of 23andme, ... For a long time, it appeared Wojcicki wouldn’t regain control of the company she left in March.
Anne Wojcicki has asked the judge in bankruptcy proceedings for 23andMe, the genetic testing company she founded and led until earlier this year, to allow additional bids for the business.
Anne Wojcicki, the co-founder and former CEO of 23andMe MEHCQ1.87%increase; green up pointing triangle, is poised to regain control of the DNA-testing company after a nonprofit she controls topped ...
23andmeA class action lawsuit, resignations, and layoffs plagued 23andMe, which filed for Chapter 11 in March. Cofounder and former CEO Anne Wojcicki won a bid to regain control of the company in ...
In a surprise twist, 23andMe founder and former CEO Anne Wojcicki is set to regain control of the DNA company's assets, according to a press release from 23andMe. In May, ...
Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' offer for the DNA-testing company in a bankruptcy auction.